Minimum Technical Preanalytical, Patient, and Clinical Context Data Elements for Cerebrospinal Fluid Liquid Biopsy: Recommendations for Public Database Submissions The feasibility of Oncotype DX ...
There's a long-standing concern among oncologists that many women with ductal carcinoma in situ (DCIS), a potential precursor to invasive breast cancer, receive more treatment than they need. The ...
Studies Presented at the 29th Annual San Antonio Breast Cancer Symposium Define Roles and Relationships of Genes Measured by Oncotype DX Recurrence Score Kaiser Permanente and the National Surgical ...
CD45-positive tumor infiltrating lymphocytes in early-stage hormone-positive, HER2-negative (ER+/HER2-) breast cancer: Correlation with proliferation and prognostic signature scores. This is an ASCO ...
- Updated RxPONDER study analysis provides further evidence that the test identifies the majority of women with early-stage, node-positive breast cancer who can avoid chemotherapy MADISON, Wis., Dec.
Title: Comprehensive comparison of prognostic signatures for breast cancer in TransATAC. Presenter: Ivana Sestak, Ph.D. Date: Friday, Dec.9, 2016: 4:15 p.m. CT. Location: S6-05; General Session 6 - ...
The Oncotype DX Breast Recurrence Score® test, which has been used by over 1.5 million patients, indicates the likelihood of your cancer recurring based on the biology of your tumor. 1,2,3,4 It is ...
MADISON, Wis., Aug. 16, 2021 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that Japan's Ministry of Health, Labor and Welfare (MHLW) has approved the Oncotype DX Breast ...
MADISON, Wis.--(BUSINESS WIRE)-- Exact Sciences Corp. (EXAS), a leading provider of cancer screening and diagnostic tests, today announced a significant milestone for its flagship Oncotype DX Breast ...
A cost-effectiveness analysis has found that Oncotype DX may not be economical to make clinical decisions on adjuvant radiation treatment in patients with DCIS. A part of precision medicine involves ...
Lymph node status in stage I hormone receptor-positive/HER2-negative breast cancer was not a good indicator of genetic-risk scores that would qualify older women for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results